Sorry, you need to enable JavaScript to visit this website.

    Pfizer Announces First Occupant in its Science Incubator

    Fabrus LLC to Develop New Antibody Technologies in Search For New Medicines  


    Pfizer today announced its first occupant for the companys Incubator a new development where scientific entrepreneurs progress their ideas towards innovative treatments for serious diseases.

    Vaughn Smider MD, PhD, an assistant professor at The Scripps Research Institute, in La Jolla CA, will work to develop a unique technology to identify antibodies that might lead to new therapies. He will build his new company, Fabrus LLC at the Incubator, located at Pfizers Research & Development site in La Jolla.

    Weve had a really warm reception from the biotech community and academic scientists, said Pfizers Alex Polinsky, who heads the Incubator. We are helping to fill the need for support and funding for early scientific work. The Incubator is a channel that brings innovation one step closer to patients. If successfully developed, Fabrus technology could lead to new therapies in many therapeutic areas.

    In total, Pfizer will invest $10 million a year to support life science start-ups based in the incubator. Pfizer continues to review research proposals and expects other occupants to move to the facility in the near future.

    Fabrus plans eventually to employ six - eight scientists, who will have laboratory and office space in part of the new incubator facility. Fabrus will receive Pfizer support for two years. At the end of the term, Pfizer has an option to acquire the company and its technologies, or Fabrus may spin out as an independent enterprise.

    The Incubator allows me to focus on science, said Dr Smider. We wont have to devote time to business complexities, like funding, equipment purchase and payroll. We also benefit from our proximity to Pfizer and its considerable scientific resources.

    During the two-year incubation period, Fabrus will work to develop novel antibody libraries, and ways to screen them against biological targets. The technology will be tested on targets in some of Pfizers 11 disease areas.

    About The Pfizer Incubator

    The Pfizer Incubator (TPI) offers scientist-entrepreneurs an opportunity to bring their medical innovations to patients. In TPI, scientist-entrepreneurs contribute innovative ideas and the ability to solve complex scientific and technical challenges, while TPI provides all necessary resources to move ideas forward into practice.

    More details are at:


    Stephen Lederer, 860-732 9783

    Product Pipeline

    Learn about specific ways our research is leading to medicines and vaccines that will benefit patients around the world.

    Corporate Fact Sheet

    For more than 170 years, Pfizer has worked to make a difference for all who rely on us.

    Coronavirus Resources

    Learn about SARS-CoV-2, the coronavirus that causes COVID-19, what you can do to stay safe and prevent the spread, and our scientific efforts to help bring an end to the current global health crisis.

    Pfizer Logo

    Our logo is shorthand for everything Pfizer represents: an image that is instantly identifiable to our colleagues, patients, the external scientific community, and the public.

    Executive Leadership

    Meet the executive leadership team, our senior-most leadership and decision-making management body who focus on major financial, strategic, and operational decisions for the entire company.